Abstract：Objective To investigate the effect of small interfering RNA (siRNA) silencing Apollon gene combined with tetramethylpyrazine (TMP) on the proliferation and apoptosis of human chronic myeloid leukemia cell line K562. Methods K562 cells were divided into blank control, negative control, and RNA interference (RNAi) group. For the RNAi group, the pGPHI-GFP-Neo-Apollon eukaryotic expression vector based on the best Apollon siRNA fragments screened out in previous experiments was constructed; the blank control group received no treatment, and the negative control group was transfected with negative plasmid vector. The mRNA and protein expression of Apollon was measured by RT-PCR and cell immunofluorescence, respectively. Additionally, TMP (320 μg/mL) was applied to set TMP, TMP+negative control, and TMP+RNAi groups. The cell viability and apoptosis rate were determined by MTT assay and flow cytometry, respectively. Results The constructed vector was stably expressed in K562 cells. The RNAi group had significantly lower mRNA and protein expression of Apollon than the blank control group and negative control (P<0.05). The RNAi group had significantly increased proliferation inhibition rate and apoptosis rate, as compared with the blank contorl group (P<0.05). The TMP+RNAi group had significantly increased proliferation inhibition rate and apoptosis rate, as compared with the RNAi, and TMP groups (P<0.05). Conclusions Apollon siRNA can significantly inhibit the proliferation and promote the apoptosis of K562 cells, and the addition of TMP can further increase the proliferation inhibition rate and apoptosis rate, suggesting that siRNA technology combined with drugs has a significant potential value in the treatment of leukemia.
JIA Xiu-Hong,XIAO Fei-Fei,LI Jian-Chang. Effect of Apollon siRNA combined with tetramethylpyrazine on prolife-ration and apoptosis of leukemia K562 cells[J]. CJCP, 2014, 16(2): 135-140.
Long J, Parkin B, Ouillette P, et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia[J]. Blood, 2010, 116(1): 71-80.
[2]
Sung KW, Choi J, Hwang YK, et al. Overexpression of apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia[J]. Clin Cancer Res, 2007, 13(17): 5109-5114.
Srinivasula SM, Ashwell JD. IAPs: what's in a Name?[J]. Mol Cell, 2008, 30(2): 123-135.
[5]
Bartke T, Pohl C, Pvrowolakis G, et al. Dual role of BRUCE as an antiapoptotic IAP and a chemeric E2/E3 ubiquitin Ligase[J]. Mol Cell, 2004, 14(6): 801-811.
[6]
Smolewski P, Robak T. Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies[J]. Curr Mol Med, 2011, 11(8): 633-649.
[7]
Ismail EA, Mahmoud HM, Tawfik LM, et al. BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis[J]. Eur J Haematol, 2012, 88(2): 118-127.
Amundson SA, Myers TG, Scudiero DS, et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines[J]. Cancer Res, 2000, 60(21): 6101-6110．
Pennati M, Millo E, Gandellini P, et al. RNA interferencemediated validation of survivin and Apollon/BRUCE as new therapeutic targets for cancer therapy[J]. Curr Top Med Chem, 2012, 12(2): 69-78.
